2021 年第 11 期 第 16 卷

新疆地区维吾尔族和汉族冠心病合并血脂异常患者有机阴离子转运体家族1B1*5基因多态性分析

Gene polymorphism of solute carrier organic anion transporter family member 1B1*5 in Uygur and Han patients with coronary atherosclerotic heart disease and dyslipidemia in Xinjiang area

作者：王婷婷1王凤霞2李红健1于鲁海1孙力1

英文作者：Wang Tingting1 Wang Fengxia2 Li Hongjian1 Yu Luhai1 Sun Li1

单位：1新疆维吾尔自治区人民医院药学部新疆维吾尔自治区临床药学研究所，乌鲁木齐830001；2新疆维吾尔自治区人民医院心内科，乌鲁木齐830001

英文单位：1Department of Pharmacy People′s Hospital of Xinjiang Uygur Autonomous Region Institute of Clinical Pharmacy of Xinjiang Uygur Autonomous Region Urumqi 830001 China; 2Department of Cardiology People′s Hospital of Xinjiang Uygur Autonomous Region Urumqi 830001 China

关键词：冠心病（冠状动脉粥样硬化性心脏病）；维吾尔族；汉族；血脂异常；有机阴离子转运体家族1B1 

英文关键词：Coronaryatheroscleroticheartdisease;Uygur;Han;Dyslipidemia;Solutecarrierorganicaniontransporterfamilymember1B1

• 摘要：

• 目的 分析有机阴离子转运体家族1B1（SLCO1B1）*5基因型和等位基因在新疆地区维吾尔族和汉族冠心病（冠状动脉粥样硬化性心脏病）合并血脂异常患者中的分布特征，为制定他汀类药物个体化用药方案、提高调脂疗效、降低不良反应发生率提供用药依据。方法 选取2017年7月至2019年8月就诊于新疆维吾尔自治区人民医院的冠心病合并血脂异常维吾尔族和汉族患者。采用荧光原位杂交技术检测患者SLCO1B1*5基因多态性，采用Hardy-Weinberg平衡检验样本的群体代表性，分析新疆地区维吾尔族和汉族患者SLCO1B1*5基因型和等位基因频率的差异。结果 本研究共纳入720例冠心病合并血脂异常患者，其中维吾尔族311例（43.2%）、汉族409例（56.8%）。维吾尔族和汉族患者SLCO1B1*5基因型和等位基因分布频率均符合Hardy-Weinberg平衡定律(均P＞0.05)，研究对象具有群体代表性。维吾尔族患者SLCO1B1*5基因型 CC、CT、TT的分布频率分别为0.6%（2/311）、19.9%（62/311）、79.4%（247/311），等位基因C、T频率分别为10.6%（66/622）、89.4%（556/622）。汉族患者SLCO1B1*5基因型CC、CT、TT的分布频率分别为1.5%（6/409）、20.8%（85/409）、77.8%（318/409），等位基因C、T频率分别为11.9%（97/818）、88.1%（721/818）。新疆地区维吾尔族和汉族冠心病合并血脂异常患者SLCO1B1*5基因型和等位基因频率差异均无统计学意义(χ2=1.093，P=0.548； χ2=0.621，P=0.459)。结论 根据SLCO1B1*5基因多态性为维吾尔族、汉族冠心病合并血脂异常患者制定他汀类药物个体化用药方案时，无需考虑民族间差异性。

• Objective To analyze the distribution characteristics of genotype and allele frequencies of solute carrier organic anion transporter family member 1B1 (SLCO1B1)*5 in Uygur and Han patients with coronary atherosclerotic heart disease (CHD) complicated with dyslipidemia in Xingjiang area, so as to provide evidence for developing individualized statins medication regimen, improving efficacy of lipid regulation and reducing the incidence of adverse reactions. Methods  From July 2017 to August 2019, Uygur and Han patients with CHD complicated with dyslipidemia admitted to People′s Hospital of Xinjiang Uygur Autonomous Region were enrolled. The SLCO1B1*5 gene polymorphism was detected by fluorescence in-situ hybridization technique, group representation of samples was tested by Hardy-Weinberg balance test, and differences in genotypes and allele frequencies of SLCO1B1*5 were compared between Uygur and Han patients. Results Totally 720 patients with CHD complicated with dyslipidemia were enrolled, including 311 cases(43.2%) of Uygur and 409 cases(56.8%) of Han. Genotypes and allele distribution frequencies of SLCO1B1*5 in Uygur and Han patients conformed to the Hardy-Weinberg equilibrium(both P>0.05), and the research subjects were group representation. Among Uygur patients, SLCO1B1*5 distribution frequencies of CC, CT and TT genotypes were 0.6%(2/311), 19.9%(62/311) and 79.4%(247/311), respectively; those of C and T allele were 10.6%(66/622) and 89.4%(556/622), respectively. Among Han patients, SLCO1B1*5 distribution frequencies of CC, CT and TT genotypes were 1.5%(6/409), 20.8%(85/409) and 77.8%(318/409), respectively; those of C and T allele were 11.9%(97/818) and 88.1%(721/818), respectively. There were no statistically significant differences in genotypes and allele frequencies of SLCO1B1*5 between Uygur and Han patients with CHD complicated with dyslipidemia (χ2=1.093, P=0.548; χ2=0.621, P=0.459). Conclusion When developing an individualized statins regimen based on SLCO1B1*5 polymorphisms for Uyghur and Han patients with CHD complicated with dyslipidemia, there is no need to consider the inter ethnic variability.